StockData
Lyell Immunopharma, Inc. logo

Lyell Immunopharma, Inc. (LYEL) stock

LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$13.80+0.22 (+1.62%)

Close on Nov 20, 2026Market cap $338.17MP/E –Yield –

Lyell Immunopharma free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Lyell Immunopharma's free cash flow for the twelve months ending Jun 30, 2026 was -$133.97M. For fiscal 2025 it was -$150.80M. The highest annual figure on record is $23.43M in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$150.80M–
FY2024Dec 31, 2024-$162.86M–
FY2023Dec 31, 2023-$166.38M–
FY2022Dec 31, 2022-$193.83M–
FY2021Dec 31, 2021-$191.75M–
FY2020Dec 31, 2020-$212.36M-1006.5%
FY2019Dec 31, 2019$23.43M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$34.18M–
Q1 FY2026Mar 31, 2026-$38.60M–
Q4 FY2025Dec 31, 2025-$32.56M–
Q3 FY2025Sep 30, 2025-$28.64M–
Q2 FY2025Jun 30, 2025-$34.63M–
Q1 FY2025Mar 31, 2025-$54.98M–
Q4 FY2024Dec 31, 2024-$47.29M–
Q3 FY2024Sep 30, 2024-$35.10M–
Q2 FY2024Jun 30, 2024-$38.43M–
Q1 FY2024Mar 31, 2024-$42.05M–
Q4 FY2023Dec 31, 2023-$40.66M–
Q3 FY2023Sep 30, 2023-$37.88M–
Q2 FY2023Jun 30, 2023-$40.09M–
Q1 FY2023Mar 31, 2023-$47.75M–
Q4 FY2022Dec 31, 2022-$44.85M–
Q3 FY2022Sep 30, 2022-$39.89M–
Q2 FY2022Jun 30, 2022-$51.50M–
Q1 FY2022Mar 31, 2022-$57.59M–
Q4 FY2021Dec 31, 2021-$43.48M–
Q3 FY2021Sep 30, 2021-$37.09M–
Q2 FY2021Jun 30, 2021-$58.39M–
Q1 FY2021Mar 31, 2021-$52.79M–
Q4 FY2020Dec 31, 2020-$51.61M–
Q3 FY2020Sep 30, 2020-$34.27M–

More Lyell Immunopharma figures

See a number that looks wrong?